Proteomics in cancer vaccine development

Expert Review of Proteomics

Volumn 2, Issue 2, 2005, Pages 229-241

  Shoshan, Stacy H ^a   Admon, Arie ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

2D PAGE; Antigens; Cancer vaccine; DRiPs; HLA; HPLC; Mass spectroscopy; MHC; Protein array; Proteomics; Tumor immulnology

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LEUKOCYTE ANTIGEN;

CANCER CELL CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SEROLOGY; TRANSLATION REGULATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEIN BIOSYNTHESIS; PROTEOMICS; RIBOSOMES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 17244363159     PISSN: 14789450     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789450.2.2.229     Document Type: Review

References (133)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report often original cases. 1893. Clin. Orthop. (262), 3-11 (1991).
2. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3(9), 666-675 (2003).
3. Rosenberg SA. Shedding light on immunotherapy for cancer. W. Engl. J. Med. 350(14), 1461 (2004).
4. Gilboa E. The promise of cancer vaccines. Nature Rev. Cancer 4(5), 401-411 (2004).
5. Berzofsky JA, Terabe M, Oh S. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515-1525 (2004).
6. Seliger B, Ritz U, Abele R et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61(24), 8647-8650 (2001).
7. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann. Rev. Immunol. 22, 329-360 (2004).
8. Lotze MT, Papamichail M. A primer on cancer immunology and immunotherapy. Cancer Immunol. Immunother. 53(3), 135-138 (2004).
9. Garcia-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. Eur. J. Immunogenet. 30(3), 177-183 (2003).
10. Ludewig B, Ochsenbein AF, Odermatt B et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191(5), 795-804 (2000).
11. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc. Natl Acad. Sci. USA 96(10), 5340-5342 (1999).
12. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).
13. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19(1), 81-84 (1996).
14. Kim CJ, Parkinson DR, Marincola F. Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J. Immunother. 21(1), 1-16 (1998).
15. Nair S, Boczkowski D. RNA-transfected dendritic cells. Expert Rev. Vaccines 1(4), 507-513 (2002).
16. Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62(20), 5845-5852 (2002).
17. Pecher G. DNA-based tumor vaccines. Onkologie 25(6), 528-532 (2002).
18. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94(11), 805-818 (2002).
19. Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53(3), 187-195 (2004). Identification approach for human leukocyte antigen peptides displayed in tumor cells based on combining the antigen prediction with direct biochemical analysis.
20. Van Der Bruggen P, Zhang Y et al. Tumor-specific shared antigenic peptides recognized by human T-cells. Immunol. Rev. 188, 51-64 (2002).
21. Shoshan SH, Admon A. MHC-bound antigens and proteomics for novel target discovery. Pharmacogenomics 5(7), 845-859 (2004).
22. Sette A, Livingston B, McKinney D et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29(3-4), 271-276 (2001).
23. Dudley ME, Wunderlich JR, Robbins PF. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002). Currently the most effective immunotherapy approach for solid tumors based on adoptive grafting of tumor infiltrating lymphocytes.
24. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J. Am. Coll. Surg. 198(5), 685-696 (2004).
25. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nature Med. 10(9), 887-892 (2004).
26. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3(7), 611-618 (2002).
27. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T-cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999).
28. Kalos M. Tumor antigen-specific T-cells and cancer immunotherapy: current issues and future prospects. Vaccine 21(7-8), 781-786 (2003).
29. Waldmann TA. Immunotherapy: past, present and future. Nature Med. 9(3), 269-277 (2003).
30. Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr. Opin. Investig. Drugs 2(1), 133-135 (2001).
31. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T-cells: March 2004 update. Cancer Immunol. Immunother. 7, 7 (2004).
32. Scanlan MJ, Cure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188, 22-32 (2002).
33. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T-lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60(4), 1028-1034 (2000).
34. Nair SK, Morse M, Boczkowski D et al. Induction of tumor-specific cytotoxic T-lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235(4), 540-549 (2002).
35. Constantin CM, Bonney EE, Altman JD, Strickland OL. Major histocompatibility complex (MHC) tetramer technology: an evaluation. Biol. Res. Nurs. 4(2), 115-127 (2002).
36. Nagorsen D, Marincola FM. How to analyze ex vivo T-cell responses in cancer patients. In vivo 16(6), 519-525 (2002).
37. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9(2), 641-649 (2003).
38. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15(2), 131-137 (2003).
39. Lally KM, Mocellin S, Ohnmacht GA et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 93(6), 841-847 (2001).
40. Lonchay C, van der Bruggen P, Connerotte T et al. Correlation between tumor regression and T-cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14631-14638 (2004). Antigen spread immune response leading to the effect of other antigens from those used for vaccination.
41. Ahram M, Emmert-Buck MR. Approaches to proteomic analysis of human tumors. Methods Mol. Biol. 222, 375-384 (2003).
42. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3(1), 9-15 (2003).
43. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
44. Hirsch J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 287(1), L1-L23 (2004).
45. Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nature Genet. 33(Suppl), 311-323 (2003).
46. Zhu H, Bilgin M, Snyder M. Proteomics. Ann. Rev. Biochem. 72, 783-812 (2003).
47. Naour FL, Brichory F, Beretta L, Hanash SM. Identification of tumor-associated antigens using proteomics. Technol. Cancer Res. Treat. 1(4), 257-262 (2002).
48. Purcell AW, Gorman JJ. Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell. Proteomics 3(3), 193-208 (2004).
49. Anderson NG, Matheson A, Anderson NL. Back to the future: the human protein index (HPI) and the agenda for postproteomic biology. Proteomics 1(1), 3-12 (2001).
50. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
51. Nesvizhskii AI, Aebersold R. Analysis, statistical validation and dissemination of large-scale proteomics data sets generated by tandem MS. Drug Discov. Today 9(4), 173-181 (2004).
52. Link AJ, Eng J, Schieltz DM et al. Direct analysis of protein complexes using mass spectrometry. Nature Biotechnol. 17(7), 676-682 (1999).
53. Wang H, Hanash S. Multi-dimensional liquid phase based separations in proteomics. J Chromatogr, B. Analyt. Technol. Biomed. Life Sci. 787(1), 11-18 (2003).
54. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol. 17(10), 994-999 (1999).
55. Chaput N, Taieb J, Schartz NE, Andre F, Angevin E, Zitvogel L. Exosome-based immunotherapy. Cancer Immunol. Immunother. 53(3), 234-239 (2004).
56. Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Med. 7(3), 297-303 (2001).
57. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15(1), 24-30 (2004).
58. Zhu H, Snyder M. Protein chip technology. Curr. Opin. Chem. Biol. 7(1), 55-63 (2003).
59. Jager D, Taverna C, Zippelius A, Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother. 53(3), 144-147 (2004).
60. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol. Immunother. 53(3), 139-143 (2004).
61. Ji H, Whitehead RH, Reid GE, Moritz RL, Ward LD, Simpson RJ. Two-dimensional electrophoretic analysis of proteins expressed by normal and cancerous human crypts: application of mass spectrometry to peptide-mass fingerprinting. Electrophoresis 15(3-4), 391-405 (1994). One of the early uses of 2D polyacrylamide gel electrophoresis for the analysis of tumor proteins.
62. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 411(6835), 375-379 (2001).
63. Celis JE, Gromov P, Cabezon T et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 3(4), 327-344 (2004).
64. Prasannan L, Misek DE, Hinderer R, Michon J, Geiger JD, Hanash SM. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin. Cancer Res. 6(10), 3949-3956 (2000).
65. Bard MP, Hegmans JP, Hemmes A et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell. Mol. Biol. 31(1), 114-121 (2004).
66. Wolters DA, Washburn MP, Yates JR III. An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 73(23), 5683-5690 (2001).
67. Wu CC, MacCoss MJ. Shotgun proteomics: tools for the analysis of complex biological systems. Curr. Opin. Mol. Ther. 4(3), 242-250 (2002).
68. Hamler RL, Zhu K, Buchanan NS et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 4(3), 562-577 (2004).
69. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res. 10(3), 981-987 (2004). A fine example of the use of matrix-assisted laser desorption/ionization mass spectrometry scanning of tumor tissues and its implication on prognosis.
70. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin. Boochem. 37(7), 579-583 (2004).
71. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49(8), 1272-1275 (2003).
72. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol. 1(3), E65 (2003). Description of arrayed major histocompatibility complex molecules as a tool for discovery of the responsive T-cells.
73. Nam MJ, Madoz-Gurpide J, Wang H et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3(11), 2108-2115 (2003).
74. Yan F, Sreekumar A, Laxman B, Chinnaiyan AM, Lubman DM, Barder TJ. Protein microarrays using liquid phase fractionation of cell lysates. Proteomics 3(7), 1228-1235 (2003).
75. Hong SH, Misek DE, Wang H et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 64(15), 5504-5510 (2004).
76. Bouwman K, Qiu J, Zhou H et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 3(11), 2200-2207 (2003).
77. Qiu J, Madoz-Gurpide J, Misek DE et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J. Proteome Res. 3(2), 261-267 (2004).
78. Gembitsky DS, Lawlor K, Jacovina A, Yaneva M, Tempst P. A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. Mol. Cell. Proteomics 3(11), 1102-1118 (2004).
79. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovi S. Towards patient-specific tumor antigen selection for vaccination. Immunol. Rev. 188(1), 164-176 (2002).
80. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94(5), 1914-1918 (1997).
81. Jager E, Gnjatic S, Nagata Y et al. Induction of primary NY-ESO-1 immunity: CD8+ T-lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl Acad. Sci. USA 97(22), 12198-12203 (2000).
82. Klade CS, Voss T, Krystek E et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1(7), 890-898 (2001). Identification of tumor proteins as targets for serum antibodies in cancer patients.
83. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61(21), 7908-7912 (2001). Identification of tumor proteins as targets for serum antibodies in cancer patients.
84. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics 1(3), 197-203 (2002).
85. Mischo A, Wadle A, Watzig K et al. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun. 3, 5 (2003).
86. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Ann. Rev. Immunol. 16, 323-358 (1998).
87. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T-lymphocyte responses. Ann. Rev. Immunol. 17, 51-88 (1999).
88. Rodriguez PC, Zea AH, Ochoa AC. Mechanisms of tumor evasion from the immune response. Cancer Chemother. Biol. Response Modif. 21, 351-364 (2003).
89. Berinstein N. Overview of therapeutic vaccination approaches for cancer. Semin. Oncol. 30(3 Suppl. 8), 1-8 (2003).
90. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int. Arch. Allergy Immunol. 133(2), 179-197 (2004).
91. Wang JY, Hsieh JS, Chen CC et al. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J. Surg. Res. 120(2), 242-248 (2004).
92. Iba T, Kigawa J, Kanamori Y et al. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci. 95(5), 418-423 (2004).
93. Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res. Treat 38(1), 27-39 (1996).
94. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624-2632 (2002).
95. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50(1), 3-15 (2001).
96. Mocellin S, Rossi CR, Nitti D, Lise M, Marincola FM. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta 1653(2), 61-71 (2003).
97. Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1263 (1992). Establishment of the direct biochemical approach for discovery of major histocompatibility complex (MHC) peptides as tumor antigen using tandem mass spectrometry.
98. Lemmel C, Stevanovic S. The use of HPLC-MS in T-cell epitope identification. Methods 29(3), 248-259 (2003).
99. Engelhard VH, Brickner AG, Zarling AL. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol. Immunol. 39(3-4), 127-137 (2002).
100. Admon A, Barnea E, Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2(6), 388-398 (2003).
101. Bonner PL, Lill JR, Hill S, Creaser CS, Rees RC. Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. J. Immunol. Methods 262(1-2), 5-19 (2002).
102. Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W. Large-scale production of class I bound peptides: assigning a signature to HLA-B* 1501. Immunogenetics 45(6), 379-385 (1997).
103. Prilliman KR, Jackson KW, Lindsey M, Wang J, Crawford D, Hildebrand WH. HLA-B15 peptide ligands are preferentially anchored at their C termini. J. Immunol. 162(12), 7277-7284 (1999).
104. Barnea E, Beer I, Patoka R et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32(1), 213-222 (2002).
105. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157(5), 1823-1826 (1996).
106. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nature Rev. Immunol. 3(12), 952-961 (2003).
107. Yewdell JW Immunology. Hide and seek in the peptidome. Science 301(5638), 1334-1335 (2003).
108. Hickman HD, Luis AD, Buchli R et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J. Immunol. 172(5), 2944-2952 (2004).
109. Princiotta MF, Finzi D, Qian SB et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18(3), 343-354 (2003).
110. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes Nature 404(6779), 770-774 (2000).
111. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules J. Cell. Sci. 114(5), J45-851 (2001).
112. Yewdell J. To DRiP or not to DRiP: generating peptide ligands for MHC class I. molecules from biosynthesized proteins. Mol. Immunol. 39(3-4), 139-146 (2002).
113. Skipper JC, Hendrickson RC, Gulden PH et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggest: a novel pathway for processing of membrane proteins. J. J Exp. Med. 183(2), 527-534 (1996).
114. Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T-cell recognition. Immunity 6(3), 273-281 (1997).
115. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192(12), 1755-1762 (2000).
116. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25(11), 1106-1118 (2003).
117. Schirch V, Delle Fratte S, di Salvo M. Detection of isoAspartate residues as a posttranslational modification of proteins and peptides. Methods Mol. Biol. 194, 269-276 (2002).
118. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427(6971), 252-256 (2004). MHC peptide formed by splicing in the proteasome.
119. Vigneron N, Stroobant V, Chapiro J et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304(5670), 587-590 (2004). MHC peptide formed by splicing ih the proteasome.
120. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T-lymphocytes. Immunol. Rev. 188, 177-182 (2002).
121. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc. 77(4), 339-349 (2002).
122. Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21(11), 2235-2242 (2000).
123. Virtanen C, Ishikawa Y, Honjoh D et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc. Natl. Acad. Sci. USA 99(19), 12357-12362 (2002).
124. Jones MB, Krutzsch H, Shu H et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2(1), 76-84 (2002).
125. Shekouh AR, Thompson CC, Prime W et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3(10), 1988-2001 (2003).
126. Friedman DB, Hill S, Keller JW et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4(3), 793-811 (2004).
127. Somiari RI, Sullivan A, Russell S et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3(10), 1863-1873 (2003).
128. Kim J, Kim SH, Lee SU et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 23(24), 4142-4156 (2002);
129. Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell Proteomics 1(2), 117-124 (2002).
130. Xu BJ, Caprioli RM, Sanders ME, Jensen RA. Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. J. Am. Soc. Mass Spectrom. 13(11), 1292-1297 (2002).
131. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5(10), 1171-1177 (1999).
132. Patel J, Krug L, Azzoli C, Gomez J, Kris M, Miller V. Targeting lethal minimal residual disease in small cell lung cancer. Semin. Oncol. 0(1), 79-85 (2003).
133. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10(9), 909-915 (2004).